JMP Securities Reaffirms “Market Outperform” Rating for DBV Technologies (NASDAQ:DBVT)

JMP Securities restated their market outperform rating on shares of DBV Technologies (NASDAQ:DBVT) in a report issued on Friday morning,Benzinga reports. The firm currently has a $10.00 target price on the stock.

Several other research firms also recently commented on DBVT. StockNews.com assumed coverage on DBV Technologies in a report on Thursday. They set a “hold” rating on the stock. HC Wainwright raised their price objective on DBV Technologies from $25.00 to $35.00 and gave the stock a “buy” rating in a report on Thursday, October 24th.

DBV Technologies Trading Up 29.8 %

Shares of NASDAQ DBVT opened at $4.97 on Friday. The business’s 50 day moving average price is $3.32 and its 200-day moving average price is $3.81. DBV Technologies has a fifty-two week low of $2.20 and a fifty-two week high of $9.49.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.